Giuliani S.p.A acquires majority stake in MIKA Pharma GmbH
MIKA Pharma GmbH announced that Giuliani S.p.A, a Milano, Italy based Pharma company has acquired a majority stake in MIKA Pharma.
Based on its proprietary nanoemulsion drug delivery technology, MIKA Pharma has developed a wide range of topical products including Diclofenac Spray, Ketoprofen Spray, and Heparin Spray. All of these products were successfully developed by MIKA Pharma and are currently registered in 32 countries. MIKA Pharma has granted licensing rights to a variety of partners to commercialise these products. In addition MIKA Pharma is developing a broad clinical pipeline of topical products for the treatment of pain and inflammation.
Bernd Seigfried, CEO of MIKA comments: "Giuliani S.p.A is the preferred strategic partner to further develop our international clinical projects. At the same time we already have products in commercial stage, here as well Giuliani S.p.A will help to faster exploit the various market opportunities."
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.